Germany
Spain
Japan
United States
This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of Afatinib or Nintedanib may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for Afatinib and Nintedanib in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy
Find out more about our recent Conversations in Oncology series of standalone meetings and preceptorship programmes.
Conversations in Oncology
Conversations in Oncology are a series of standalone medical education meetings which focus on bringing clinicans up-to-date with latest advances in the treatment of lung cancer
Preceptorship
The Boehringer Ingelheim Preceptorship programme aims to bring oncologists together for a two- to three-day long meeting, to discuss the latest advancements in the management and treatment of cancer patients. Boehringer Ingelheim provides selected oncology societies and Centers of Excellence (CoE) with an unrestricted educational grant/financial support, with the belief that all parties can benefit from the Preceptorship series. If you want to learn more about our Preceptorships and get further material please get in touch with Sandra Lieb.
